Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.

被引：2
|
作者：
Kunzmann, Volker
Ramanathan, Ramesh K.
Goldstein, David
Penenberg, Darryl Neil
Ferrara, Stefano
Lu, Brian D.
Von Hoff, Daniel D.
机构：
[1] Univ Klinikum Wurzburg, Wurzburg, Germany
[2] Mayo Clin, Scottsdale, AZ USA
[3] Univ New S Wales, Prince Wales Hosp, Canc Survivors Ctr, Sydney, NSW, Australia
[4] Celgene Corp, New York, NY USA
[5] Celgene Corp, Bouldry, Switzerland
[6] Celgene Corp, Summit, NJ USA
[7] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr, Clin Trials, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15299
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15299
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl Neil
    Ferrara, Stefano
    Lu, Brian
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
  • [4] nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen Mary
    Philip, Philip Agop
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial
    Vogel, A.
    Penenberg, D.
    McGovern, D.
    Romano, A.
    Michael, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S455 - S455
  • [6] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Goldstein, David
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.
    Reni, Michele
    Riess, Hanno
    O'Reilly, Eileen Mary
    Park, Joon Oh
    Hatoum, Hassan
    Saez, Berta Laquente
    Salminen, Tapio
    Oettle, Helmut
    Lopez, Rafael
    Dowden, Scot D.
    Karthaus, Meinolf
    Tabernero, Josep
    Van Cutsem, Eric
    Philip, Philip Agop
    Goldstein, David
    Berlin, Jordan
    Tempero, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
    Tempero, M. A.
    Cardin, D.
    Biankin, A.
    Goldstein, D.
    Moore, M.
    O'Reilly, E. M.
    Philip, P.
    Riess, H.
    Macarulla, T.
    Yung, L.
    Wei, X.
    Lu, B.
    PANCREAS, 2014, 43 (08) : 1416 - 1416
  • [9] Tumor burden reduction between primary and metastatic sites in advanced pancreatic cancer patients (pts) undergoing chemotherapy with nab-paclitaxel (Nab-P) and gemcitabine (Gem)
    Ventriglia, J.
    Laterza, M. M.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Diana, A.
    Troiani, T.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [10] Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
    Goldstein, David
    Von Hoff, Daniel D.
    Chiorean, E. Gabriela
    Reni, Michele
    Tabernero, Josep
    Ramanathan, Ramesh K.
    Aly, Abdalla
    Botteman, Marc
    Wilkersen, Julia
    Margunato-Debay, Sandra
    Lu, Brian
    Louis, Chrystal Ursula
    Renschler, Markus Frederic
    McGovern, Desmond Micahel Thomas
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345